Olga Fleming is a visionary communications leader who artfully disrupts the norms of PR, transforming companies, culture, and categories along the way. With over three decades of experience spanning global brand campaigns, scientific communications, and creative storytelling, Olga brings a rare hybrid of rigor and imagination to everything she touches.

She is one of the industry's foremost experts in healthcare communications, particularly in oncology. For more than 30 years, there has never been a moment in her career where oncology wasn’t part of her focus. Olga has helped shape campaigns that form the foundation of today’s most widely used cancer regimens, from launching the original chemotherapies, to supporting the first wave of immunotherapies and biomarker-targeted therapies. Her expertise spans almost every major pharmaceutical company and some of the most innovative biotechnology brands, supporting everything from product launches to franchise strategy.

Olga’s work has also extended to renowned institutions such as MD Anderson, St. Jude Children's Research Hospital, and Cancer Treatment Centers of America. She has led campaigns that fundamentally redefined the cancer patient experience, most notably the groundbreaking “Oncology on Canvas” initiative for Lilly Oncology and “Story Half Told,” for Pfizer, which shifted public understanding and visibility around metastatic breast cancer.

As CEO of MMC and RXMOSAIC, Olga has ushered in a new era for the agency, redefining what it means to be human-first in a data-obsessed world. Under her leadership, MMC has experienced significant growth, adding four Fortune 500 clients and earning top industry honors including Cannes Lions, Effies, PRWeek and MM+M Awards.

Named PRWeek’s 2025 Outstanding Agency Professional of the Year, Olga has shaped perceptions and driven change for brands like Amgen, Merck, Novartis, Pfizer and P&G. Her work blends emotional intelligence with scientific clarity, resulting in campaigns that not only resonate, but often set the standard.

Beyond agency life, Olga is a dedicated mentor and advocate. She serves as a ColorComm mentor, PRWeek Awards judge, and active member of the Diversity Action Alliance, and The Lagrant Foundation.

Michael Axelrod is a co-founder and Managing Partner at Nimbl Consulting, a Philadelphia-based technology solutions company. He has over 25 years of experience in operational, sales, and leadership roles across the staffing, technology consulting, management consulting, and digital transformation industries. He has extensive experience in building successful, high-performance teams in both sales and delivery. He is a passionate leader known for strong relationships with clients and employees, as well as for creating profitable and sustainable revenue streams.

In 2001, Michael founded e-brilliance, a technology consulting firm recognized by Inc. 500 and the Philadelphia Business Journal numerous times as one of the top IT consulting companies in Philadelphia. After 10 years of consistent growth, it was acquired by LiquidHub. Michael was a Partner with LiquidHub, managing their second largest account, and he was instrumental in helping sell LiquidHub to Capgemini. 

Michael received a Bachelor of Science at Ithaca College and Juris Doctorate in Law from Cardozo School of Law.

Dr. Patricia Saint Cyr-Hager (Pat) is a recognized leader in the pharmaceutical industry, known for her commitment to accelerating clinical trial execution and improving the patient’s journey to expand access to new treatments. 

With over 20 years at Bristol Myers Squibb, Patricia served as Executive Director of Hematology, Oncology & Cell Therapy Patient Advocacy, where she developed strategic partnerships that advanced clinical research and fostered collaboration across researchers, scientific societies, and patient organizations. Her leadership resulted in faster trial execution, operational cost savings, and improved satisfaction among enterprise partners. Patricia also led four biotech acquisition integrations in oncology advocacy and managed joint venture advocacy and policy plans for cardiovascular brands, demonstrating her expertise in complex partnership management. Earlier in her career, she held operational leadership roles at Schering Plough (now Merck) and Covance, gaining broad experience in clinical trial management.

Her expertise spans therapeutic areas including Cardiovascular, Oncology, Immunoscience, Virology, and Rare Diseases. Patricia has worked in both the United States and China, solving clinical trial execution and treatment access challenges. She has contributed to the approval of more than 15 drugs, leading five to commercialization, and has shaped strategic partnerships between industry, academia, research networks, and non-profit organizations to ensure patient insights are integrated into drug development.

In November 2025, Patricia was appointed Chief Operating Officer at The Daniels Network, which oversees Black Health Matters and the Black Health Matters Foundation. In this newly established position, she is responsible for expanding the organization’s national presence in health equity, patient engagement, and advocacy. She leads internal operations and develops strategic external partnerships to increase access to health information and innovation for underserved populations throughout the United States. Additionally, Patricia manages the Client Services Department and provides strategic counsel to the CEO and executive leadership across the BHM enterprise.

In December 2025, Patricia earned her Doctorate in Public Health from Walden University, further enhancing her influence within healthcare and the life sciences. Her academic credentials also include a Bachelor of Arts in Biology from Arcadia University, a Master of Arts in Administration from Rider University, and certification in entrepreneurial business management from Dartmouth.

Patricia is committed to helping young professionals and promoting community health through public service. She co-founded OneWe Reach (formerly WOCIP®) in 2015 and served on its advisory council until 2025. She sits on the Board of Trustees at Arcadia University and was recently appointed to the Board of Cancer Support Community, where she will support cancer-related initiatives.

Patricia lives at the New Jersey shore with her husband and enjoys family gatherings, travel, live concerts, and running.

Kristie Gurley is a Partner in Covington & Burling’s Washington, DC office, where she advises pharmaceutical companies on complex and evolving drug pricing and market access issues. Kristie’s advisory practice spans federal health care program coverage and reimbursement, Medicaid price reporting, agency engagement, payer contracting and formulary access, value-based contracting, and other issues under federal and state drug pricing regimes. 

In addition to regulatory counseling, Kristie advises on strategic commercial transactions, litigation opportunities, compliance and enforcement risk, and policy advocacy. Kristie previously served in the Office of the General Counsel of the U.S. Department of Health and Human Services. In this role, Kristie supported implementation of newly enacted programs under the Inflation Reduction Act, including as a lead attorney for the first cycle of the Medicare Drug Price Negotiation Program, as well as other Medicare and Medicaid initiatives such as the development of innovative drug pricing models.